Clinical Trials Logo

Generalized Pustular Psoriasis clinical trials

View clinical trials related to Generalized Pustular Psoriasis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06323356 Recruiting - Clinical trials for Generalized Pustular Psoriasis

A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Start date: March 19, 2024
Phase: Phase 3
Study type: Interventional

The main aim of this study is to check if TAK-279 improves symptoms of With Generalized Pustular Psoriasis (GPP) or Erythrodermic Psoriasis (EP) and side effect from the study treatment or TAK-279. All participants will be assigned to study treatments of TAK-279 and will be treated with TAK-279 if the participants meet the study rules. Participants will be in the study for up to 61 weeks including 52 weeks of study treatment. During the study, participants will visit their study clinic for multiple times.

NCT ID: NCT06295692 Recruiting - Clinical trials for Generalized Pustular Psoriasis

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Start date: February 9, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).

NCT ID: NCT06100991 Recruiting - Clinical trials for Generalized Pustular Psoriasis

CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry

Start date: September 19, 2023
Phase:
Study type: Observational

Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target

NCT ID: NCT06013969 Recruiting - Clinical trials for Generalized Pustular Psoriasis

A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

Start date: October 11, 2023
Phase: Phase 4
Study type: Interventional

This study is open to adults with a serious skin disease called generalized pustular psoriasis (GPP) who have repeated flares of GPP. The purpose of this study is to find out whether a medicine called spesolimab helps people with repeated flares of GPP. Participants are given a single dose of spesolimab as an infusion into a vein on the first day of an outbreak of GPP. They may be given a second dose 1 week later if doctors think it is helpful. They are also treated for additional GPP flares. During the time of the study, doctors regularly examine participants' skin for signs of GPP to see how well the treatment works and take blood samples. The doctors also regularly check participants' health and take note of any unwanted effects.

NCT ID: NCT05670821 Recruiting - Clinical trials for Generalized Pustular Psoriasis

PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms

Start date: March 29, 2023
Phase:
Study type: Observational

Non-interventional cohort study in patients with newly initiated Spesolimab to evaluate the incidence of adverse drug reactions and to understand generalized pustular psoriasis (GPP) disease activities in the real world setting.